BioNTech and Pfizer dose participants in Covid-19 vaccine trial

30th April 2020 (Last Updated April 30th, 2020 13:01)

BioNTech and Pfizer have dosed participants in the first cohort of a Phase I/II clinical trial of Covid-19 vaccine candidate BNT162 in Germany.

Dosing in the trial was commenced on 23 April and 12 participants have received the vaccine so far.

The companies also intend to trial BNT162 in the US following regulatory approval.

Read the full article here